921 related articles for article (PubMed ID: 28411193)
21. Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Wang DY; Eroglu Z; Ozgun A; Leger PD; Zhao S; Ye F; Luke JJ; Joseph RW; Haq R; Ott PA; Hodi FS; Sosman JA; Johnson DB; Buchbinder EI
Cancer Immunol Res; 2017 May; 5(5):357-362. PubMed ID: 28396509
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Lin M; Luo H; Liang S; Chen J; Liu A; Niu L; Jiang Y
J Clin Invest; 2020 May; 130(5):2560-2569. PubMed ID: 32027620
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
24. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
25. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
28. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
29. Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.
Davis EJ; Perez MC; Ayoubi N; Zhao S; Ye F; Wang DY; Sosman JA; Al-Rohil RN; Eroglu Z; Johnson DB
J Immunother; 2019; 42(6):221-227. PubMed ID: 30882548
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
31. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
32. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
[TBL] [Abstract][Full Text] [Related]
33. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Maity A; Mick R; Huang AC; George SM; Farwell MD; Lukens JN; Berman AT; Mitchell TC; Bauml J; Schuchter LM; O'Hara M; Lin LL; Demichele A; Christodouleas JP; Haas NB; Patsch DM; Hahn SM; Minn AJ; Wherry EJ; Vonderheide RH
Br J Cancer; 2018 Nov; 119(10):1200-1207. PubMed ID: 30318516
[TBL] [Abstract][Full Text] [Related]
35. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.
Lisberg A; Tucker DA; Goldman JW; Wolf B; Carroll J; Hardy A; Morris K; Linares P; Adame C; Spiegel ML; Wells C; McKenzie J; Ledezma B; Mendenhall M; Abarca P; Bornazyan K; Hunt J; Moghadam N; Chong N; Nameth D; Marx C; Madrigal J; Vangala S; Shaverdian N; Elashoff D; Garon EB
Cancer Immunol Res; 2018 Mar; 6(3):288-294. PubMed ID: 29382669
[TBL] [Abstract][Full Text] [Related]
36. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.
Haymaker CL; Kim D; Uemura M; Vence LM; Phillip A; McQuail N; Brown PD; Fernandez I; Hudgens CW; Creasy C; Hwu WJ; Sharma P; Tetzlaff MT; Allison JP; Hwu P; Bernatchez C; Diab A
Cancer Immunol Res; 2017 Feb; 5(2):100-105. PubMed ID: 28062513
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
[No Abstract] [Full Text] [Related]
40. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
